Venture Capital

Durect Corporation To Present Preliminary Data From The Ongoing Dur-928 Alcoholic Hepatitis Phase 2a Trial And Report First Quarter 2019 Financial Results

by prnewswire.com posted 1year ago 292 views
CUPERTINO, Calif., May 3, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report preliminary data from the ongoing DUR-928 alcoholic hepatitis (AH) trial and its financial results for the three months ended March 31, 2019 after the market close on...